Target Information

Target General Infomation
Target ID
T03403
Former ID
TTDS00039
Target Name
Cyclooxygenase
Synonyms
Cyclooxygenase (COX1 and COX2); PHS; Prostaglandin H2 synthase; Prostaglandin synthase
Target Type
Successful
Disease Ankylosing spondylitis [ICD9: 720; ICD10: M08.1, M45]
Asthma [ICD10: J45]
Atopic dermatitis [ICD9: 691.8, 692.9; ICD10: L00-L99]
Arthritis [ICD9: 710-719; ICD10: M00-M25]
Back pain [ICD9: 724.5,338,780; ICD10: M54, G89, R52]
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63]
Cardiovascular disorder [ICD10: I00-I99]
Chemotherapy or radiotherapy-induced mucositis [ICD9: 338, 528.0,780; ICD10: K12.3, R52, G89]
Dysmenorrhea [ICD9: 625.3; ICD10: N94.4-N94.6]
Hyperglyceridemic [ICD9: 790.29; ICD10: R73.9]
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25]
Immuno-modulator [ICD9: 135, 691.8, 692.9, 710-719, 714; ICD10: D86, L20, L20-L30, M00-M25, M05-M06]
Inflammation [ICD10: E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89]
Inflammatory bowel disease [ICD9: 555, 556; ICD10: K50, K51]
Joint and muscular pain; Ankylosing spondylitis [ICD9:719.4, 729.1, 338, 780, 720; ICD10: M25.5, M79.1, G89, R52, M08.1, M45]
Migraine [ICD9: 346; ICD10: G43]
Myocardial infarction; Cerebrovascular ischaemia [ICD9: 410, 434.91; ICD10: I21, I22, I61-I63]
Osteoarthritis of knee [ICD10: M15-M19, M47]
Osteoarthritis [ICD9: 715; ICD10: M15-M19, M47]
Otitis media [ICD10: H65-H67]
Parkinson's disease [ICD9: 332; ICD10: G20]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
Postoperative inflammation undergone cataract extraction [ICD code not available]
Platelet aggregatory [ICD10: D69.1]
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06]
Type 2 diabetes; Early nephropathy; Claudication [ICD9: 250, 250.00, 250.02, 250.4, 338, 437.6, 443.9, 453, 580-599, 671.5, 671.9,780; ICD10: E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89]
Unspecified [ICD code not available]
BioChemical Class
Oxidoreductases acting on paired donors
Target Validation
T03403
Drugs and Mode of Action
Drug(s) Aceclofenac Drug Info Approved Inflammatory disease [1], [2]
Acetaminophen Drug Info Approved Pain [3], [4]
Ampiroxicam Drug Info Approved Inflammatory disease [2]
Amtolmetin guacil Drug Info Approved Inflammatory disease [2]
Asasantin Drug Info Approved Cerebrovascular ischaemia [5]
Aspirin Drug Info Approved Pain [6], [5]
Dexibuprofen Drug Info Approved Ankylosing spondylitis [2]
Diclofenac Drug Info Approved Osteoarthritis of knee [2]
Felbinac Drug Info Approved Arthritis [2]
Fenoprofen Drug Info Approved Rheumatoid arthritis [7], [8]
Fosfosal Drug Info Approved Pain [2]
Icosapent Drug Info Approved Hyperglyceridemic [9], [10]
Ketorolac Drug Info Approved Postoperative inflammation undergone cataract extraction [2]
Lornoxicam Drug Info Approved Migraine [11], [2]
Loxoprofen gel Drug Info Approved Inflammatory disease [12], [2]
Meclofenamic acid Drug Info Approved Joint and muscular pain; Ankylosing spondylitis [13], [14], [2]
Morniflumate Drug Info Approved Otitis media [2]
Nepafenac Drug Info Approved Osteoarthritis [15], [16], [2]
Oxaprozin Drug Info Approved Rheumatoid arthritis [2]
Pelubiprofen Drug Info Approved Back pain [2]
Pravigard Drug Info Approved Myocardial infarction; Cerebrovascular ischaemia [5]
Aspirin Drug Info Phase 3 Cardiovascular disorder [6], [17], [18]
K-103-IP Drug Info Phase 3 Pain [19]
Naproxcinod Drug Info Phase 3 Inflammatory disease [20]
BN82451 Drug Info Phase 2 Parkinson's disease [21]
NCX 1022 Drug Info Phase 2 Atopic dermatitis [22]
NCX-4016 Drug Info Phase 2 Inflammation [23]
TZI-41078 Drug Info Phase 2 Arthritis [24]
4-aminosalicylate sodium (oral controlled release, ulcerative colitis), AGI Therapeutics Drug Info Phase 1 Inflammatory bowel disease [25]
SKF-105809 Drug Info Phase 1 Pain [26]
Felbinac prodrug Drug Info Preclinical Inflammatory disease [27]
Droxicam Drug Info Withdrawn from market Inflammatory disease [28]
Zomepirac Drug Info Withdrawn from market Pain [2]
Bermoprofen Drug Info Discontinued in Preregistration Inflammatory disease [29]
Pirazolac Drug Info Discontinued in Preregistration Inflammatory disease [30]
KC-764 Drug Info Discontinued in Phase 3 Platelet aggregatory [31]
Benzydamine Drug Info Discontinued in Phase 2 Chemotherapy or radiotherapy-induced mucositis [32]
D-7193 Drug Info Discontinued in Phase 2 Immuno-modulator [33]
FS-205-397 Drug Info Discontinued in Phase 2 Pain [34]
NCX-4016 Drug Info Discontinued in Phase 2 Type 2 diabetes; Early nephropathy; Claudication [5]
NCX-701 Drug Info Discontinued in Phase 2 Pain [35]
PSD-508 Drug Info Discontinued in Phase 2 Dysmenorrhea [36]
D-1367 Drug Info Discontinued in Phase 1 Arthritis [37]
Eltenac Drug Info Discontinued in Phase 1 Arthritis [38]
F-11105 Drug Info Discontinued in Phase 1 Asthma [39]
E-5110 Drug Info Terminated Inflammatory disease [40]
Florifenine Drug Info Terminated Inflammatory disease [41]
NMI-1182 Drug Info Terminated Inflammatory disease [42]
RP-66364 Drug Info Terminated Inflammatory disease [43]
S-14080 Drug Info Terminated Inflammatory disease [44]
WY-28342 Drug Info Terminated Rheumatoid arthritis [45]
Diclofenac Drug Info Investigative Unspecified [46], [2]
Modulator 4-aminosalicylate sodium (oral controlled release, ulcerative colitis), AGI Therapeutics Drug Info [47]
Aceclofenac Drug Info [48], [2]
Ampiroxicam Drug Info [49], [2]
Amtolmetin guacil Drug Info [50], [2]
Bermoprofen Drug Info [51]
D-1367 Drug Info [52]
D-7193 Drug Info [53]
Dexibuprofen Drug Info [54], [2]
Diclofenac Drug Info [46], [2]
Droxicam Drug Info [55]
E-5110 Drug Info [56]
Eltenac Drug Info [57]
Felbinac Drug Info [58], [2]
Felbinac prodrug Drug Info [59], [2]
Florifenine Drug Info [60]
Fosfosal Drug Info [61], [62]
FS-205-397 Drug Info [63], [2]
K-103-IP Drug Info [19]
KC-764 Drug Info [64], [2]
Lornoxicam Drug Info [65], [2]
Morniflumate Drug Info [66], [2]
Naproxcinod Drug Info [67]
NCX 1022 Drug Info [68]
NCX-701 Drug Info [69], [70]
Pelubiprofen Drug Info [71], [2]
Pirazolac Drug Info [72]
RP-66364 Drug Info [73]
S-14080 Drug Info [74]
SKF-105809 Drug Info [26]
TZI-41078 Drug Info [24], [2]
WY-28342 Drug Info [75]
Zomepirac Drug Info [76], [2]
Inhibitor Acetaminophen Drug Info [77], [78], [79]
Asasantin Drug Info [5]
Aspirin Drug Info [80]
Benzydamine Drug Info [32]
BN82451 Drug Info [81]
F-11105 Drug Info [53]
Fenoprofen Drug Info [82], [83]
Ketorolac Drug Info [84]
Loxoprofen gel Drug Info [85], [2]
Meclofenamic acid Drug Info [86], [87]
NCX-4016 Drug Info [5]
Nepafenac Drug Info [88], [2]
NMI-1182 Drug Info [89]
Oxaprozin Drug Info [83]
Pravigard Drug Info [5]
PSD-508 Drug Info [90]
Binder Icosapent Drug Info [91]
References
REF 1ClinicalTrials.gov (NCT01912066) A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601. U.S. National Institutes of Health.
REF 2Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 3FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018337.
REF 4(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5239).
REF 5Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
REF 6(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4139).
REF 7(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4820).
REF 8FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072267.
REF 9(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7441).
REF 10Drug information of Icosapent, Health Canada, 2007.
REF 11ClinicalTrials.gov (NCT00997750) Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome. U.S. National Institutes of Health.
REF 12ClinicalTrials.gov (NCT00994461) Study Of Celecoxib In Healthy Subjects. U.S. National Institutes of Health.
REF 13Pharmacology, pharmacokinetics, and therapeutic use of meclofenamate sodium. Clin J Pain. 1991;7 Suppl 1:S44-8.
REF 14(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7219).
REF 15(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7564).
REF 162005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
REF 17The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8.
REF 18Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5.
REF 19ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health.
REF 20ClinicalTrials.gov (NCT00541489) Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip. U.S. National Institutes of Health.
REF 21ClinicalTrials.gov (NCT02231580) Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients. U.S. National Institutes of Health.
REF 22Clinical pipeline report, company report or official report of NicOx SA.
REF 23Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7. Epub 2005 Sep 6.
REF 24Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10.
REF 25Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022712)
REF 26Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7.
REF 27Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008689)
REF 28Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003115)
REF 29Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000932)
REF 30Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000980)
REF 31Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001148)
REF 32Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
REF 33Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007192)
REF 34Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003851)
REF 35Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014096)
REF 36Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027456)
REF 37Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005889)
REF 38Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003785)
REF 39Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010557)
REF 40Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000953)
REF 41Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003826)
REF 42Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020060)
REF 43Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003795)
REF 44S14080, a peripheral analgesic acting by release of an endogenous circulating opioid-like substance. Br J Pharmacol. 1995 Jan;114(2):303-8.
REF 45Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005582)
REF 46Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
REF 475-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res. 2012 Apr;32(4):1193-202.
REF 48Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
REF 49Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7. Epub 2006 Mar 15.
REF 50Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18.
REF 51Prolongation of antipyretic action and reduction of gastric ulcerogenicity in the rat by controlled-release granules of bermoprofen, a new nonsteroidal anti-inflammatory drug. J Pharm Sci. 1991 Sep;80(9):876-80.
REF 52US patent application no. 2007,0072,861, Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
REF 53US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
REF 54Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
REF 55Pharmacokinetic profile of droxicam. Eur J Rheumatol Inflamm. 1991;11(4):10-4.
REF 56Effect of E-5110, a novel non-steroidal anti-inflammatory drug, on trimethadione metabolism as an indicator of hepatic drug-oxidizing capacity in beagle dog. Xenobiotica. 1994 Mar;24(3):215-20.
REF 57Effect of eltenac in horses with induced endotoxaemia. Equine Vet J Suppl. 2000 Jun;(32):26-31.
REF 58A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7.
REF 59Predicting Cyclooxygenase Inhibition by Three??imensional Pharmacophoric Profiling. Part I: Model Generation, Validation and Applicability in Ethnopharmacology. Molecular Informatics 01/2010; 29(1??):75 - 86.
REF 60A study of the novel anti-inflammatory agent florifenine topical anti-inflammatory activity and influence on arachidonic acid metabolism and neutrophil functions. Naunyn Schmiedebergs Arch Pharmacol.1995 Mar;351(3):298-304.
REF 61Pharmacological study of 2-phosphonoxybenzoic acid (fosfosal), a new analgesic drug. Arzneimittelforschung. 1980;30(7):1091-8.
REF 62Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
REF 63FS 205-397: a new antipyretic analgesic with a paracetamol-like profile of activity but lack of acute hepatotoxicity in mice. Life Sci. 1988;43(11):905-12.
REF 64Clinical and preclinical pharmacology of KC-764, a novel antiplatelet agent. Nihon Rinsho. 1992 Feb;50(2):379-84.
REF 65The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
REF 66Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
REF 67Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57.
REF 68Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25. Epub 2004 Aug 16.
REF 69Nitroparacetamol (NCX-701) and pain: first in a series of novel analgesics. CNS Drug Rev. 2007 Fall;13(3):279-95.
REF 70Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin. Br J Pharmacol. 2009 September; 158(2): 601-609.
REF 71Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-?B inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603.
REF 72Differential dosing study of pirazolac, a new non-steroidal anti-inflammatory agent, in patients with rheumatoid arthritis. Curr Med Res Opin. 1985;9(8):542-7.
REF 73WO patent application no. 1997,0297,75, Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist.
REF 74US patent application no. 7,022,689, 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor.
REF 75Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. J Med Chem. 1995 Apr 28;38(9):1473-81.
REF 76Effect of preischemia cyclooxygenase inhibition by zomepirac sodium on reflow, cerebral autoregulation, and EEG recovery in the cat after global ischemia. J Cereb Blood Flow Metab. 1986 Dec;6(6):691-702.
REF 77COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31. Epub 2002 Sep 19.
REF 78COX-3: just another COX or the solitary elusive target of paracetamol? Lancet. 2003 Mar 22;361(9362):981-2.
REF 79Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
REF 80Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
REF 81Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.
REF 82Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. Arch Pharm Res. 2007 Jan;30(1):64-74.
REF 83The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
REF 84Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32. Epub 2007 Mar 16.
REF 85Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder. Mod Rheumatol. 2014 Jan;24(1):144-9.
REF 86Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
REF 87Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann N Y Acad Sci. 1994 Apr 18;714:136-42.
REF 88Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15.
REF 89NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology. 2005;12(5-6):521-34.
REF 90CN patent application no. 104797935, A method for prognosis and treatment of cancer metastasis.
REF 91Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. Epub 2002 Dec 1.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.